Web Analytics
Cổ phiếu UTHR (NASDAQ) | UNITED THERAPEUTICS CORPORATION – Phân tích Deepscope
MARKET

Select Market Data Region

UTHR — UNITED THERAPEUTICS CORPORATION (Healthcare >> Drug Manufacturers - Specialty & Generic)

UTHR FAQ

What is UTHR's P/E ratio?

UNITED THERAPEUTICS CORPORATION (UTHR) currently trades at a P/E ratio of 18.12.

What is UTHR's ROE?

UNITED THERAPEUTICS CORPORATION reports a Return on Equity (ROE) of 21.82%.

What is UTHR's dividend yield?

UNITED THERAPEUTICS CORPORATION offers a dividend yield of 0.00%.

What is UTHR's Deepscope Quality Score?

Deepscope rates UTHR's overall financial quality at 85 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy UTHR?

Deepscope's AI Timing Score for UTHR is 56 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does UTHR belong to?

UNITED THERAPEUTICS CORPORATION is classified under the Healthcare >> Drug Manufacturers - Specialty & Generic sector on the NASDAQ exchange.

Stock Check   *Daily update data at 9:30 AM*
(Price: 2026-06-03 | FS: 2026-03-31)

UTHR

UNITED THERAPEUTICS CORPORATION
USD 549.47
9.42 (1.74%) Day Change
18.12
P/E
0.14
D/E
21.8%
ROE
19.2%
ROA
0.00%
Div Yield
0.78
PEG

UNITED THERAPEUTICS CORPORATION
TYPE: STOCK
MARKET: NASDAQ

Compare   Watchlist   Myport
USD 549.47
Price
9.42 (1.74%)
Day Change
NEWS SCORE: 99

UTHR Chất lượng tổng thể của cố phiếu Rất tốt ( Chất lượng = 85) nhưng Thời điểm mua ...(Sign In to See)...

85

QUALITY

Signal
OUTPERFORM
Signal Description
Company financial health is Good
Reason
[-] Tốc độ tăng trưởng ROE dưới mức tiêu chí của chúng tôi.
Tốc độ tăng trưởng biên lợi nhuận ròng dưới mức tiêu chí của chúng tôi

88 Sign in

TIMING

Signal
OUTPERFORM
Signal Descri...
Good
Reason
Lorem ipsum dolor sit amet
Sign in to see timing analysis
Unlock timing signals and detailed reasons
Sign in free

Chi tiết hơn, sẽ thấy rằng các yếu tố chất lượng Không tốt lắm , Sức khỏe tài chính Không tốt lắm , và khả năng kiếm lợi nhuận Tốt , ...

Yếu tố Chất lượng 57%
X
X
X
X
  In Recommendations? In "Invest - GOOD" Section
  Select Rate 0.00 From 30 days period
  Watch Rate 0.00 From 30 days period
  News Score 99
  Magic Formula Rank by ROA
583
  Magic Formula Rank by ROE
583
  Magic Formula Rank by ROIC
609
  Price 549.47
  PBV / Sector
3.95 / 2.65
  Earning Per Share 30.33
  PE / Sector
18.12 / 22.64
  PEG or PE/Growth / Sector
0.78 / 0.11
  Average 1M Daily Value
228.83 M
GREAT
  Average 1W Daily Value
245.05 M
GREAT
Yếu tố Kỹ thuật 28%
  MACD
  MACD Signal
  MACD Divergence
  RSI
  Stochastic Oscillator K
  Stochastic Oscillator D
  ADX
  Avg 5 day Timing Score
Sức khỏe tài chính 58%
X
X
X
X
  DE / Sector
  DE Average / Sector
  DE Change Average (%) / Sector
  Current Ratio / Sector
  Current Ratio Average / Sector
  Current Ratio Change Average (%) / Sector
  Quick Ratio / Sector
  Quick Ratio Average / Sector
  Quick Ratio Change Average (%) / Sector
  FCF/Share / Sector
  FCF/Share Average / Sector
  FCF/Share Change Average (%) / Sector
Khả năng kiếm lợi nhuận 72%
X
X
X
X
X
X
X
  GPM (%) / Sector
  GPM Average (%) / Sector
  GPM Change Average (%) / Sector
  OPM (%) / Sector
  OPM Average (%) / Sector
  OPM Change Average (%) / Sector
  NPM (%) / Sector
40.61 / 15.98
GREAT
  NPM Average (%) / Sector
40.79 / -16.38
GREAT
  NPM Change Average (%) / Sector
2.16 / 113.39
  Asset Turnover / Sector
  Asset Turnover Average / Sector
  Asset Turnover Change Average (%) / Sector
  ROA (%) / Sector
19.17 / 8.16
GOOD
  ROA Average (%) / Sector
15.62 / 2.38
GOOD
  ROA Change Average (%) / Sector
12.47 / 108.63
GOOD
  ROE (%) / Sector
21.82 / -0.19
GOOD
  ROE Average (%) / Sector
18.16 / 7.40
  ROE Change Average (%) / Sector
9.66 / 371.95
  ROIC (%) / Sector
  ROIC Average (%) / Sector
  ROIC Change Average (%) / Sector
Lợi tức cho nhà đầu tư 4%
X
  Dividend (%) / Sector
N/A / 0.54
  Dividend Average (%) / Sector
N/A / 3.08
  Dividend Change Average (%) / Sector
N/A / 15.11
Chi tiết đăng ký
X
  Analyze Date 2026-06-04 09:24:06
  Symbol UTHR
  Name UNITED THERAPEUTICS CORPORATION
  Sector Healthcare >> Drug Manufacturers - Specialty & Generic
  Market NASDAQ
  Listed Shares 42.45 M
  Par Value N/A
  Calculated From Quarter
  Sign N/A
  Market Cap (M.USD) / Sector Average 23,323.20 / 9,480.84
Tin tức, Dự báo ước tính
  Estimation Consensus See at WSJ.com
  Full details See at WSJ.com
  Chart See in Chart feature
  News See at Yahoo Finance

Address: 1000 Spring Street, Silver Spring, MD, United States, 20910

Phone: 301 608 9292

Website: https://www.unither.com

Employees: 1,400

Sector: Healthcare >> Drug Manufacturers - Specialty & Generic

Description: United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, it is involved in developing RemunityPRO Pump and Ralinepag for the treatment of PAH;and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. Further, it provides preclinical products, including EVLP/CLES, for lung transplant; UKidney, UHeart, UThymoKidney, a development-stage gene-edited porcine kidneys and hearts for xenotransplantation; ULobe, for allogeneic regenerative medicine; ULung, for autologous regenerative medicine; IVIVA Kidney, for autologous regenerative medicine; miroliver, for allogeneic regenerative medicine; and mirokidney, for allogeneic regenerative medicine. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was founded in 1996 and is headquartered in Silver Spring, Maryland.

ME vs SECTOR Healthcare >> Drug Manufacturers - Specialty & Generic

UTHR (ME)
Sector Peers
Bubble size = Market Cap

Click a bubble to view stock details  ·  Bubble size represents market capitalization share

News

Smart picks. Just WOW stocks/funds/ETFs. No noise like other tools.
UTHR
UTHR
USD 549.47 (1.74%)
+ Watch + Port Chart